FTC’s AndroGel pay-for-delay claims against Teva ‘without merit,’ judge says
The Federal Trade Commission has failed to show that Teva Pharmaceuticals took part in an anticompetitive agreement to delay a generic version of the testosterone treatment AndroGel, a federal judge said.The...To view the full article, register now.
Already a subscriber? Click here to view full article